MedCity News November 13, 2024
Frank Vinluan

Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs.

When Johnson & Johnson backed down from its proposal to modify the way it supplies certain drugs under the 340B statute, it hinted litigation could be its next step to effect changes that address what it says is rampant abuse of a program originally intended to make medicines more accessible to underserved patients. The pharmaceutical giant has now taken that legal step.

J&J is suing the Department of Health and Human Services and the Health...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Health System / Hospital, Pharma, Pharma / Biotech, Provider
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
Advancing Cancer Care: The Role of Radiopharmaceuticals in Precision Medicine
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report

Share This Article